Birinapant is under clinical development by IGM Biosciences and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Birinapant’s likelihood of approval (LoA) and phase transition for Recurrent Head And Neck Cancer Squamous Cell Carcinoma took place on 13 Jan 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Birinapant Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Birinapant is under development for the treatment of recurrent head and neck squamous cell carcinoma. The drug candidate is administered through intravenous infusion and subcutaneous route. TL32711 is a small molecule peptidomimetic of SMAC (second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple inhibitors of apoptosis proteins (IAPs). Birinapant was under development for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia (CMML), hepatitis B, peritoneal cancer, epithelial ovarian cancer, fallopian cancer, lymphoma and metastatic colorectal cancer, pancreatic cancer, carcinoma, colorectal cancer and melanoma, relapsed/refractory acute myelocytic leukaemia, acute lymphocytic leukaemia (ALL), myelodysplastic syndrome.
IGM Biosciences overview
IGM Biosciences operates as a biotechnology company that develops novel antibodies for the treatment of cancer and other diseases. The company’s pipeline product portfolio includes IGM-2323is an IgM-based CD20 x CD3 bispecific antibody T cell engager, IGM-8444 is an IgM antibody targeting Death Receptor, IGM-7354 is a targeted IL-15 immune stimulating antibody and IGM-2644 is a T cell engaging IgM antibody targeting CD38 for the treatment of patients with multiple myeloma. It utilizes IgM and IgA antibodies technology for developing their products. The company serves in the therapeutic areas of immuno oncology. IGM Biosciences is headquartered in Mountain View, California, the US.
Quick View Birinapant LOA Data
|Highest Development Stage|